Novo Nordisk posts strong Q1 as Wegovy drives global GLP-1 momentum

The standout story remains Wegovy, particularly its new oral formulation

Lilly’s Omvoh shows rare long-term remission milestone in ulcerative colitis

Eli Lilly unveils $4.5 bn Indiana expansion

The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies

National Health Authority set to host AB PM-JAY Auto-Adjudication Hackathon Grand Finale

More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science

Samsung Bioepis’ Pembrolizumab biosimilar SB27 meets phase 1 PK endpoints

The proposed biosimilar to Keytruda demonstrated pharmacokinetic bioequivalence in a multicountry Phase 1 study involving non-small cell lung cancer patients

Ajanta Pharma Q4 FY26 revenue surges 21% to Rs. 1,422 Crore; PAT climbs 18%

FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter

Alkem Laboratories receives relief as GST demand of Rs 69.65 crore dropped on appeal

The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty

Laurus Labs Q4 profit rises to Rs. 279 crore, FY26 revenue up 23%

The company reported robust revenue and profit growth for FY26, supported by strong CDMO performance, improving margins, and expansion across advanced manufacturing platforms

Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility

The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026

Revvity tops Q1 estimates and unveils plans to exit China immunodiagnostics

The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue